Business
India’s Corporate Earnings Show Broad-Based Growth In Q1 FY26, Says Motilal Oswal
Last Updated:
‘Q1 earnings, perceived as the ‘Crossover quarter’, marked a transition from the subdued low-single-digit earnings growth of FY25 to sustainable double-digit growth,’ says MOFSL.
MOFSL expects Nifty-50 EPS growth to recover to nearly 9% in FY26 (from just 1% in FY25), aided by supportive macro conditions.
Corporate India entered FY26 on a stronger footing, according to a report by Motilal Oswal Financial Services (MOFSL), which called the June 2025 quarter (Q1FY26) the “Crossover Quarter”. According to the brokerage, earnings transitioned from the muted single-digit growth of FY25 to a more sustainable double-digit trajectory, driven by better sectoral breadth and resilience in financials, energy, and telecom.
“Corporate earnings for 1QFY26, perceived as the ‘Crossover quarter’, marked a transition from the subdued low-single-digit earnings growth of FY25 to a sustainable double-digit growth trajectory. A key highlight of the quarter was better sectoral breadth of earnings growth. Of the 25 sectors under our coverage, 16 delivered double-digit growth, eight reported single-digit growth, and only one sector experienced a decline in PAT,” Motilal Oswal said in the report titled ‘India Strategy’.
Broad-Based Earnings Growth
Out of 25 sectors under MOFSL’s coverage, 16 reported double-digit profit growth, eight recorded single-digit gains, and only one posted a decline. Aggregate earnings of the companies tracked by Motilal Oswal rose 11% YoY, ahead of estimates. Excluding financials, profits rose 13% YoY, while excluding global commodities (metals and oil & gas), growth stood at 9% YoY.
Oil & Gas (+27% YoY), telecom (loss-to-profit), NBFCs (+14%), PSU banks (+7%), technology (+7%), cement (+51%), and healthcare (+11%) contributed nearly 77% of incremental profit accretion. Automobiles (-3%) weighed on performance.
Nifty-50 Stretches Single-Digit Streak
Nifty-50 earnings rose 8% YoY in Q1, the fifth straight quarter of single-digit profit growth since the pandemic. Reliance Industries, Bharti Airtel, SBI, HDFC Bank, and ICICI Bank alone accounted for 77% of incremental earnings, while Coal India, Tata Motors, ONGC, HUL, Nestle, and others dragged overall growth, according to the brokerage.
Market-Cap Segment Trends
“large-caps (87 companies) posted an earnings growth of 10% YoY – similar to the overall universe. Mid-caps (92 companies) have extended their streak of the past two quarters and yet again delivered a strong earnings growth of 24% YoY (vs. our est. of 20%),” Motilal Oswal stated.
Large-caps: Earnings grew 10% YoY, in line with estimates.
Mid-caps: Continued to outperform, rising 24% YoY versus expectations of 20%, with 17 of 22 sectors delivering double-digit profit growth.
Small-caps: Lagged significantly, with earnings falling 11% YoY against expectations of flat growth. Nearly half of the small-cap coverage universe missed estimates.
Earnings Outlook
For FY26, MOFSL projects its coverage universe to clock 12% profit growth, led by financials (+8%), metals (+19%), and oil & gas (+9%). Mid-caps are expected to deliver 21% growth, compared with 10% for large-caps and 34% for small-caps.
However, the brokerage noted that earnings downgrades continued to outpace upgrades, with the Nifty FY26 EPS estimate cut by 1.2% to Rs 1,108, primarily due to weaker forecasts for ONGC, Reliance Industries, Axis Bank, Power Grid, and HDFC Bank.
Sectoral Highlights
Banks: In-line results but with margin pressure, especially at private lenders.
Autos: Mixed quarter; OEMs posted modest growth, while ancillaries outperformed.
Consumer: Demand recovery intact, revenue up 8.3% YoY.
Oil & Gas: Profits surged but missed estimates due to OMC underperformance.
Technology: Weak revenue momentum amid macro headwinds.
Metals: Robust operating performance lifted profits 59% YoY.
MOFSL expects Nifty-50 EPS growth to recover to nearly 9% in FY26 (from just 1% in FY25), aided by supportive macro conditions. While market volatility may persist due to global tariff concerns, the brokerage believes India remains well-placed for modest gains, with mid-caps offering relatively better earnings visibility.
The report maintained an overweight stance on BFSI, consumer discretionary, industrials, healthcare, and telecom, while staying underweight on oil & gas, cement, real estate, and metals.
Haris is Deputy News Editor (Business) at news18.com. He writes on various issues related to personal finance, markets, economy and companies. Having over a decade of experience in financial journalism, Haris h…Read More
Haris is Deputy News Editor (Business) at news18.com. He writes on various issues related to personal finance, markets, economy and companies. Having over a decade of experience in financial journalism, Haris h… Read More
view comments
Read More
Motorists are facing higher fuel prices ahead of Easter break due to the conflict in the Middle East, the RAC says.
Source link
Hyderabad: Pharma player Hetero on Friday said it has rolled out exports of its generic semaglutide injection portfolio as part of a multi-year plan to widen access to treatments for type 2 diabetes and obesity in more than 75 countries.The Hyderabad-based pharmaceutical company said initial rollouts are under way in Africa, Asia and the Middle East, with additional launches planned in other markets subject to regulatory approvals.The injectable therapies will be sold under the brand names Truglyx, Rolmodl and Moto G. Semaglutide belongs to the GLP-1 class of medicines, which are used in diabetes care and weight management.Hetero said the export launch is part of its broader strategy to improve access to advanced cardio-metabolic therapies, particularly in emerging markets.The company said the products will be offered in multi-dose disposable pen devices designed in line with innovator formats and will be available in several strengths, including 0.25 mg, 0.5 mg, 1 mg, 2 mg, 1.7 mg and 2.4 mg, allowing dosing flexibility for both diabetes and obesity treatment.Hetero said it is also awaiting approval from India’s Central Drugs Standard Control Organisation (CDSCO) after completing clinical trials in type 2 diabetes and obesity and plans an India launch after regulatory clearance.Hetero managing director Dr Vamsi Krishna Bandi said the company aims to provide high-quality, affordable generic semaglutide through a single global product platform backed by its manufacturing and development capabilities.He said Hetero would use its commercial networks across Asia, the Middle East, Africa and Latin America to support supply and access. The Hyderabad-headquartered Hetero operates in more than 145 countries and employs over 30,000 people.
Business
India-US trade deal update: Piyush Goyal meets USTR Jamieson Greer, discusses next steps in BTA talks – The Times of India
Commerce and industry minister Piyush Goyal on Friday met US Trade Representative Jamieson Greer and reviewed the next steps in negotiations for the proposed India-US bilateral trade agreement (BTA).The meeting took place on the sidelines of the 14th ministerial conference (MC14) of the World Trade Organisation in Yaounde, Cameroon, where both sides also exchanged views on issues related to the WTO agenda.“Had a very productive discussion with @USTradeRep Jamieson Greer on the sidelines of the WTO Ministerial Conference. Exchanged views on the #WTOMC14 agenda, next steps in the India-US BTA negotiations and explored ways to further deepen our economic cooperation and bilateral trade ties,” Goyal said in a social media post.The development comes amid ongoing efforts by both countries to finalise an interim trade pact. Last month, India and the US announced that they had finalised a framework for the first phase of the agreement, though it is yet to be signed.The two sides had earlier announced a trade deal on February 2, followed by a joint statement on February 7 outlining the contours of the agreement.As part of the framework, the US had agreed to reduce tariffs on Indian goods to 18%. However, the tariff structure has since undergone changes after the US Supreme Court struck down sweeping tariffs imposed under earlier measures.Following the ruling, US President Donald Trump introduced a 10% tariff on all countries for a period of 150 days starting February 24.In view of these developments, a planned meeting between chief negotiators of India and the US — aimed at finalising the legal text of the agreement — has been postponed. The pact was earlier expected to be signed this month.An official had earlier said that the interim trade agreement would be signed once the new global tariff framework of the US is fully in place.
Asda boss rejects profiteering claims as petrol price tops 150p
Britney Spears turns a new page after recent legal trauma
This Premium Sennheiser Soundbar Is $1,000 Off
-
Entertainment1 week agoVal Kilmer revived 1 year after death through AI
-
Fashion7 days agoChina’s textile & apparel exports surge 17% to $50 bn in Jan-Feb 2026
-
Business1 week agoVideo: The Effects of High Oil Prices
-
Business7 days agoFlipkart group CFO to leave co amid IPO plans – The Times of India
-
Sports7 days agoRating Adidas’ 2026 World Cup away shirts: Argentina, Spain, Mexico and more
-
Sports7 days agoAmerican Conference Commissioner Tim Pernetti thanks Trump for Army-Navy game executive order
-
Tech1 week ago
The Corsair 4000D RS PC Case Keeps Your System Cool
-
Fashion1 week agoThe hidden $1.62 war tax now embedded in every garment you source